𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

✍ Scribed by Patrick B. Johnston; David J. Inwards; Joseph P. Colgan; Betsy R. Laplant; Brian F. Kabat; Thomas M. Habermann; Ivana N. Micallef; Luis F. Porrata; Stephen M. Ansell; Craig B. Reeder; Vivek Roy; Thomas E. Witzig

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
217 KB
Volume
85
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II trial of peg-L-asparaginase i
A phase II trial of peg-L-asparaginase in the treatment of non-hodgkins lymphoma
✍ Hyman B. Muss; Nancy Spell; Diane Scudiery; Robert L. Capizzi; M. Robert Cooper; πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 388 KB

A polyethylene glycol conjugate of L-asparaginase (PEGLA) was administered to 21 patients with refractory non-Hodgkin's lymphoma. The dose given was 2,000 mu/m2 intramuscularly every 2 weeks. Eligibility required at least one prior trial of chemotherapy and ambulatory performance status. At entry, a

Phase II trial of etoposide and cisplati
Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351
✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated